Literature DB >> 10449831

Anaplastic thyroid carcinoma survival.

P E Voutilainen1, M Multanen, R K Haapiainen, A K Leppäniemi, A H Sivula.   

Abstract

Anaplastic thyroid carcinoma is a rare, highly malignant tumor of elderly people. The purpose of this retrospective study was to characterize the patient population and to detect a potential subgroup with better prognosis or any intervention that would be useful. From 1967 through 1994 a total of 33 anaplastic thyroid carcinomas were operated on at the Second Department of Surgery, Helsinki University Central Hospital. There were 26 females and 7 males with mean age of 66.0 years (range 36-89 years). At the time of diagnosis 16 of 33 patients had distant metastases, and 32 of 33 of the tumors had invaded the thyroid capsule. Disease-specific survival was 9.7% (95% confidence interval from 2.0% to 25.9%) at 1 year using the product limit survival analysis. In the stepwise Cox proportional hazards regression model, local resectability (p = 0.0002), presence of distant metastases at diagnosis (p = 0.0014), radiotherapy (p = 0.014), and radioiodine ablation (p = 0.039) were independent prognostic factors. We concluded that even though statistically significant, independent, prognostic factors can be found the survival of the patients with the best prognostic characteristics is still poor. Only one patient, who had an anaplastic carcinoma focus within an encapsulated follicular thyroid carcinoma, survived in this series. At present there seems to be no surgical treatment that would be efficient for treating symptomatic anaplastic thyroid carcinoma.

Entities:  

Mesh:

Year:  1999        PMID: 10449831     DOI: 10.1007/s002689900610

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  20 in total

Review 1.  Anaplastic thyroid carcinoma.

Authors:  P I Haigh
Journal:  Curr Treat Options Oncol       Date:  2000-10

2.  Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination.

Authors:  Akira Yoshida; Kiminori Sugino; Iwao Sugitani; Akira Miyauchi
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

Review 3.  Thyroid and aging.

Authors:  Mouhammed Habra; Nicholas J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2005-05       Impact factor: 6.514

4.  Paucicellular variant of anaplastic thyroid carcinoma: report of two cases.

Authors:  J C Canos; A Serrano; X Matias-Guiu
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

5.  Nonconventional papillary thyroid carcinomas with pleomorphic tumor giant cells: a diagnostic pitfall with anaplastic carcinoma.

Authors:  Juliette Hommell-Fontaine; Angela Borda; Florence Ragage; Nicole Berger; Myriam Decaussin-Petrucci
Journal:  Virchows Arch       Date:  2010-04-23       Impact factor: 4.064

6.  Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival.

Authors:  Sabine Wächter; C Vorländer; J Schabram; I Mintziras; I Fülber; J Manoharan; K Holzer; D K Bartsch; E Maurer
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-02-14       Impact factor: 2.503

7.  Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Authors:  R C Smallridge; J A Copland; M S Brose; J T Wadsworth; Y Houvras; M E Menefee; K C Bible; M H Shah; A W Gramza; J P Klopper; L A Marlow; M G Heckman; R Von Roemeling
Journal:  J Clin Endocrinol Metab       Date:  2013-04-15       Impact factor: 5.958

Review 8.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

Review 9.  Surgical options in undifferentiated thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

Review 10.  Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?

Authors:  Vesna Bisof; Zoran Rakusic; Marija Despot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-03       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.